We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+4.42%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$85.6M
AUM Growth
+$5.45M
Cap. Flow
+$1.9M
Cap. Flow %
2.22%
Top 10 Hldgs %
85.3%
Holding
14
New
3
Increased
1
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$6.82M
2
WAT icon
Waters Corp
WAT
+$6.51M
3
CI icon
Cigna
CI
+$6.27M
4
MCK icon
McKesson
MCK
+$858K

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$10.4M
2
GILD icon
Gilead Sciences
GILD
+$1.61M
3
BIIB icon
Biogen
BIIB
+$1.36M
4
ICCC icon
ImmuCell
ICCC
+$1.33M
5
LGND icon
Ligand Pharmaceuticals
LGND
+$1.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
1
McKesson
MCK
$104B
$10.5M 12.3%
68,600
+5,500
+9% +$858K
ELV icon
2
Elevance Health
ELV
$81.5B
$10.5M 12.24%
55,200
– –
ANIK icon
3
Anika Therapeutics
ANIK
$215M
$6.67M 7.79%
115,000
-10,000
-8% -$523K
CI icon
4
Cigna
CI
$78.4B
$6.58M 7.68%
+35,200
New +$6.27M
CRL icon
5
Charles River Laboratories
CRL
$11.3B
$6.57M 7.67%
60,812
-9,400
-13% -$966K
LGND icon
6
Ligand Pharmaceuticals
LGND
$5.77B
$6.52M 7.62%
76,784
-13,305
-15% -$1.05M
PFE icon
7
Pfizer
PFE
$143B
$6.47M 7.56%
191,090
-24,769
-11% -$796K
WAT icon
8
Waters Corp
WAT
$37.3B
$6.45M 7.53%
+35,900
New +$6.51M
BIIB icon
9
Biogen
BIIB
$30.9B
$6.39M 7.46%
20,400
-4,600
-18% -$1.36M
LH icon
10
Labcorp
LH
$25.2B
$6.39M 7.46%
49,237
-4,074
-8% -$543K
MDT icon
11
Medtronic
MDT
$112B
$6.38M 7.46%
+82,100
New +$6.82M
GILD icon
12
Gilead Sciences
GILD
$165B
$6.21M 7.25%
76,600
-21,000
-22% -$1.61M
COR icon
13
Cencora
COR
$62B
– –
-109,700
Closed -$10.4M
ICCC icon
14
ImmuCell
ICCC
$99.6M
– –
-182,133
Closed -$1.33M

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
SC
Saybrook Capital Winston Salem, North Carolina $371M AUM 13.23% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

HealthInvest Partners's Q3 2017 Portfolio in Review

As of Q3 2017, HealthInvest Partners held 14 positions worth $85.6M, up 6.8% from $80.2M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

HealthInvest Partners's Q3 2017 filing shows 3 new, 1 increased, 7 reduced and 2 closed positions. Its largest new stake was Medtronic: 82,100 shares worth $6.38M. The largest sale was Cencora, an estimated $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q3 2017 buy was Medtronic: 82,100 shares worth $6.38M.
  • HealthInvest Partners added most to McKesson in Q3 2017, an estimated $858K increase.
  • HealthInvest Partners's biggest Q3 2017 reduction was Gilead Sciences, cutting an estimated $1.61M.
  • HealthInvest Partners fully exited Cencora in Q3 2017, selling an estimated $10.4M.
  • HealthInvest Partners's ten largest holdings make up 85% of its $85.6M portfolio in Q3 2017.
  • HealthInvest Partners opened 3 new positions and closed 2 in Q3 2017.
  • HealthInvest Partners's portfolio value rose 6.8% quarter-over-quarter to $85.6M.

Based on HealthInvest Partners's 13F filing for Q3 2017, filed 13 Nov 2017.